Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.

Abstract

Recent pharmacogenetic studies on irinotecan have revealed the impact of UDP glucuronosyltransferase (UGT) 1A1*28 on severe irinotecan toxicities. Although the clinical role of UGT1A1*6, which is specifically detected in East Asian patients, in irinotecan toxicities is suggested, clear evidence remains limited. To examine the impact of *6, the association of UGT1A1 genotypes with severe irinotecan toxicities was retrospectively investigated in Japanese cancer patients. A significant *6-dependent increase in the incidence of grade 3 or 4 neutropenia was observed in 49 patients on irinotecan monotherapy (p=0.012). This study further clarifies the clinical importance of *6 in irinotecan therapy in East Asians.

• Authors: Kimie Sai, Yoshiro Saito, Hiromi Sakamoto, Kuniaki Shirao, Koichi Kurose, Mayumi Saeki, Shogo Ozawa, Nahoko Kaniwa, Setsuo Hirohashi, Nagahiro Saijo, Jun-ichi Sawada, Teruhiko Yoshida
• Journal: Cancer letters (Cancer Lett) Vol. 261 Issue 2 Pg. 165-71 (Mar 18 2008) ISSN: 0304-3835 [Print] Ireland
• PMID: 18082937 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents, Phytogenic
• Irinotecan
• UGT1A1 enzyme
• Glucuronosyltransferase
• Bilirubin
• Camptothecin

Topics

• Adult
• Aged
• Antineoplastic Agents, Phytogenic (adverse effects)
• Asian People (genetics)
• Bilirubin (blood)
• Camptothecin (adverse effects, analogs & derivatives)
• Female
• Genotype
• Glucuronosyltransferase (genetics, metabolism)
• Humans
• Incidence
• Irinotecan
• Japan (epidemiology)
• Male
• Middle Aged
• Neoplasms (drug therapy, genetics, pathology)
• Polymorphism, Genetic
• Retrospective Studies